GSK plc (NYSE:GSK) is considered one of the best undervalued stocks to buy under $50, with a Hold rating and £16 price target from Deutsche Bank. The company recently reported fiscal Q3 earnings, showing significant growth in vaccines, specialty medicines, and general medicines, with total sales up 7% AER and 8% CER.

Core operating profit for GSK plc rose 11% in fiscal Q3, with core EPS growing by 14%. The growth was driven by Specialty Medicines and Vaccines sales, increased royalty income, and investments in R&D in Oncology and Vaccines. The company also upgraded its 2025 guidance, expecting core EPS growth of 10% to 12% and core operating profit growth of 9% to 11%.

Formerly known as GlaxoSmithKline, GSK plc is a global healthcare and biopharmaceutical company based in the UK. It develops vaccines, medications, and consumer health products, with a strong focus on vaccines, immunology, and respiratory therapies. The company also works on cancer treatments for various types of cancer.

While GSK shows potential as an investment, some AI stocks may offer greater upside potential and lower downside risk. Investors seeking undervalued AI stocks can explore options that benefit from Trump-era tariffs and the onshoring trend. For more insights, read our free report on the best short-term AI stock.

Read more at Yahoo Finance: Deutsche Bank Maintains a Hold Rating on GSK plc (GSK)